RELMADA THERAPEUTICS, INC. Proceeds from Debt, Net of Issuance Costs
RELMADA THERAPEUTICS, INC. (RLMD) reported Proceeds from Debt, Net of Issuance Costs of $13.28 million for the 0-month period ending 2022-04-08, per its 10-Q filed 2022-05-05.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2022-11-10
- RELMADA THERAPEUTICS, INC. proceeds from debt, net of issuance costs for fiscal 2021 was $161.23M.
| Period end | Proceeds from Debt, Net of Issuance Costs 0 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|
| 2022-04-08 | $13.28M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $161.23M 10-K · filed 2022-03-25 | |
| 2020-05-15 | $42.73M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |